top of page
Reta
Reta

Reta

$85.00Price
Size
10mg
15mg
20mg
30mg
Quantity

Retatrutide

Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist — the next-generation weight loss and diabetes compound from Eli Lilly. Phase III TRIUMPH-1 data (May 2026) showed 28.3% weight loss (70.3 lbs) at 80 weeks on 12mg weekly, with an extension cohort reaching 30.3% (85.0 lbs). ADA 2026 data confirmed 60.6% sleep apnea reduction and 46% normoglycemia in type 2 diabetes. NDA submission expected Q4 2026; FDA approval realistically late 2027.

Mechanism

Retatrutide activates three hormone receptors simultaneously:

GLP-1 (appetite suppression)

GIP (insulin sensitivity and glucose-dependent insulin secretion)

Glucagon (increased energy expenditure and hepatic fat oxidation)

The C20 fatty acid conjugation with Aib residues provides DPP-4 resistance, extending half-life. This triple activation produces superior weight loss and metabolic control compared to single or dual agonists.

Potential Benefits

  • Superior weight loss: 24.2% mean reduction (significantly higher than Tirzepatide's 20.9%)

  • Improved glycemic control with glucose-dependent regulation

  • Enhanced energy expenditure through glucagon activation

  • Cardiovascular lipid improvements and blood pressure optimization

  • Sleep apnea reduction (60.6% AHI improvement)

  • Normoglycemia achievement in type 2 diabetes (46%)

  • Sustained weight management with continuous therapy

Why It's Being Researched

Retatrutide addresses the ceiling effect of dual agonists (GLP-1/GIP). Adding glucagon activation increases energy expenditure and hepatic fat oxidation — mechanisms neither Semaglutide nor Tirzepatide fully leverage. Phase III data shows superior weight loss and metabolic outcomes. The triple mechanism also improves cardiovascular risk factors beyond weight loss alone, making it a potential standard-of-care for obesity and type 2 diabetes.

Interesting Facts

  • 39 amino acids with C20 fatty acid conjugation for extended half-life

  • Triple agonist — activates three hormone receptors vs. Tirzepatide's two

  • 28.3% weight loss at 12mg (vs. Tirzepatide's ~20.9% at 15mg)


Stacking — Retatrutide

Avoid Completely

  • Semaglutide, Tirzepatide, Bioglutide, Mazdutide — all share GLP-1/GIP/glucagon overlap. Combining causes severe hypoglycemia, excessive nausea, vomiting, and gastroparesis with no added benefit. Do not stack.

Use With Caution

  • Eloralintide — both produce significant GI effects. No combination data exists; concomitant use not supported by clinical evidence. Monitor nausea and GI tolerance closely.

  • GHRP-2 — GHRP-2 promotes GH release with potential transient insulin resistance; Retatrutide improves metabolic parameters. Net metabolic impact unclear. Requires regular glucose and lipid monitoring.

Compatible Stacks

  • NAD+ — different cellular systems. NAD+ supports cellular energy and DNA repair; may support metabolic adaptation during weight loss.

  • BPC-157 — different targets. BPC-157 promotes tissue repair; may provide GI protective benefits during Retatrutide use.

  • HCG — entirely different pathways. Commonly combined by men on TRT managing weight.

  • GHK-CU, TB-500 — tissue repair compounds that work through different mechanisms. Safe to combine for comprehensive health optimization.

  • LIPO-C — lipotropics enhance liver fat processing; Retatrutide targets incretin receptors. May be used together in clinical weight loss protocols.

Safety Note

Retatrutide carries confirmed dysesthesia risk (5.1–12.5% at therapeutic doses) and dose-dependent GI effects (73–94% nausea at higher doses). Monthly glucose and lipid monitoring essential. Do not combine with other GLP-1/GIP/glucagon agonists.



RESEARCH PURPOSES ONLY

NOT AVAILABLE FOR HUMAN CONSUMPTION

    bottom of page